StockpollyBeta
Get App
Popularity #3,369
TLX · NASDAQ · Biotechnology

Telix Pharmaceuticals (TLX)

Commercializes prostate-cancer imaging agents while developing radiopharmaceutical diagnostics and treatments.

$11.24
vs last close−0.71 (−5.94%)

  1. Telix Pharmaceuticals Limited (TLX) Discusses Strategic Overview and Oncology Pipeline at Research and Development Day Transcript

    Seeking AlphaEarnings

  2. Telix Pharmaceuticals Limited (TLX) M&A Call Transcript

    Seeking Alpha

  3. Telix Pharmaceuticals: 'Buy' On Pixclara FDA Approval And TLX591-Tx Part 2 Advancement

    Seeking Alpha

  4. FDA Approves Telix Pharmaceuticals Brain Cancer Imaging Drug

    Benzinga

  5. FDA Approves Telix's Brain Cancer Imaging Drug Pixclara

    GlobeNewsWire

  6. Telix Completes Enrollment in Phase 3 BiPASS Study, Aligns with FDA on NDA Pathway

    GlobeNewsWireClinical

  7. Telix Appoints David Gill as Chair

    GlobeNewsWireLeadership

  8. Telix Pharmaceuticals Limited (TLX) Q2 2026 Earnings Call Transcript

    Seeking AlphaEarnings

  9. Telix Pharmaceuticals H1 Earnings Call Highlights

    MarketBeatEarnings

  10. Telix 2026 Half-Year Results: Strong Commercial Execution and Momentum in Late-Stage Pipeline

    GlobeNewsWireEarnings

  11. Telix Pharmaceuticals: The Radiopharma Operating System Is The Real Moat

    Seeking Alpha

  12. Does Telix Pharmaceuticals Limited (TLX) Have the Potential to Rally 86.17% as Wall Street Analysts Expect?

    Zacks Investment Research

  13. TLX591-Tx ProstACT SELECT Study Published in Cancers Journal

    GlobeNewsWire

  14. Telix Q2 Revenue US$247M, Strong Momentum and Pipeline Progress

    GlobeNewsWire

  15. Telix Doses First Patient in Phase 3 LUTEON Trial of TLX250-Tx for Renal Cancer

    GlobeNewsWire

  16. First Patients Dosed in OPTIMAL-e Trial for Earlier Stage Prostate Cancer

    GlobeNewsWire

  17. Telix Pharmaceuticals Limited (TLX) Discusses Neurologic Oncology Portfolio and Advances in Therapeutic and Diagnostic Agents Transcript

    Seeking Alpha

  18. Telix Educational Webinar: Neuro-Oncology Portfolio Update and Physician Perspectives on Future Therapeutic Directions

    GlobeNewsWire

  19. Telix and United Imaging Announce Strategic Theranostics Collaboration

    GlobeNewsWire

  20. Telix Pharmaceuticals: PSMA Radiopharmaceutical Player Is Revving Up

    Seeking Alpha

  21. New Publication Demonstrates TLX250-Px (Zircaix®) Potential in Diagnosing Kidney Cancers Beyond ccRCC

    GlobeNewsWire

  22. Telix Pharmaceuticals Limited (TLX) Discusses Advances in PSMA Therapy and Insights from the OPTIMAL-PSMA Trial with TLX597 Transcript

    Seeking Alpha

  23. OPTIMAL-PSMA Trial of TLX597-Tx Next Generation RLT Presented at IPCS 2026 Highlighting Therapeutic Potential in Prostate Cancer

    GlobeNewsWire

  24. Educational Webinar: Unlocking the Potential of PSMA Therapy, A Next‑Generation Portfolio Approach

    GlobeNewsWire